Hikal Ltd

Know More
NSEBSE

278.85-1.85 (-0.66%)

03:49 PM,1st Mar 2024

278.00-2.20 (-0.79%)

04:01 PM,1st Mar 2024

BSE : 524735

NSE : HIKAL

Sector : Health care

ISIN Code : INE475B01022

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Mar 01 2024 | 04:01 PM IST

Market Cap (₹ Cr)

3438

Turnover (₹ Cr)

0.44

Volume (Shares)

158418

Face Value

2

52-WK High

329.00

52-WK High Date

05 Jun 2023

52-WK Low

250.10

52-WK Low Date

02 Nov 2023

All Time High

742.00

All Time High Date

17 Aug 2021

All Time Low

4.24

All Time Low Date

02 Nov 2001

Hikal Ltd

Hikal Limited incorporated on July 08th 1988 has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals crop protection animal health biocides and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates specialty chemicals active pharma ingredients and contract research activities. Presently it is operating in the crop protection and pharmaceuticals space.The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US Japan Europe Canada South East Asia LATAM India and RoW. Apart from this it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division it offer human health and animal health products.Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C. Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996 Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck & Co. USA chose Hikal as a partner to outsource Thiabendazole (TBZ a fungicide). Since the capacity at Mahad was inadequate Hikal built second greenfield site a state-of-the-art manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufacturing facility near Mumbai in collaboration with Merck & Co Inc USA for the manufacture of a post-harvest fungicide. It received the prestigious '5 star Safety Award' from British Safety Council' UK for high standards maintained at the Taloja Site.During 1999-2000 the company has acquired an Agrochemical manufacturing site at Panoli Gujarat from Novartis India Limited. The Company's status as an Export House has been elevated to that of a Trading House. In 2001 it entered the pharmaceuticals business when it acquired the R&D Unit and Bulk Drug Manufacturing Facility of Wintac Ltd at Bangalore in Karnataka. In 2004 it built a brand new API plant post-acquisition and received USFDA certification. The Bangalore API Plant approved by USFDA and Australian TGA. During 2004-05 A 100% EOU plant for pharamaceutical intermediates is being set up. This unit is expected to be operational in the first half of the coming year. During 2004-05 the company is establishing a state-of-the-art R&D facility in Pune and this research facility is expected to be operational in early 2006.In Aug. 2004 the company has entered into an agreement with Bayer CropScience AG to manufacture and supply Agro biochemical intermediates and has set up a plant to manufacture this products in Mahad Plant. In 2005 the company made an agreement with Crompton Corporation USA to manufacture and market a New Generation Crop protection product. In Nov. 2005 the company entered into a JV agreement with a subsidiary company of Sinochem Corporation China.During 2005-2006 the company made a strategic investment in Jiangsu Chemstar Industries Co (a subsidiary company of Sinochem Corporation China A Fortune 500 company). The company acquired 10% stake in the year. The companies production capacity of Crop protection products and Pharmaceutical products stood at 4436 MTn and 180 MT respectively. The Company commenced export of Gabapentine to the US and Canada markets during FY 2006-07. It acquired Marsing & Co. A/S Denmark and commenced marketing and distribution of APIs in various countries. The Company increased investment to 16% in Jiangsu Chemstar Industries Co. Ltd. (a subsidiary company of Sinochem Corporation China A FORTUNE 500 company) in FY'2007. During the year it started supply of new Crop Protection product to one of the leading multinational companies. In Pharma plant its existing Intermediate products registered increase in volumes and two new Pharma products were manufactured at Panoli site. R&D unit labs got upgraded and two new labs were added during the year 2007-08.In 2008 the Company established Acoris Research Ltd. a contract research facility at the International Biotech Park Pune which is fully operational. In 2009 it expanded manufacturing capabilities. Construction of the new multi-purpose active ingredients plant for crop protection at the Taloja site was completed. It commissioned several new multipurpose API plants at the US FDA approved site in Bangalore. It commissioned a new multipurpose pharma intermediates plant at Panoli. Long-term contracts with global life sciences companies had a substantial impact on business. It signed long-term contract for a patented molecule with a leading multinational company.As per the Scheme of Arrangement effective from 1st April 2012 the Research and Development activity of Acoris demerged with Hika. Acoris formerly a subsidiary is now a division of Hikal and further strengthened its capabilities both in terms of manpower as well as technical capabilities.During the year 2013 it signed a manufacturing agreement with a specialty US based food ingredient company. It completed initial supplies for advanced intermediates to one of the largest U.S. biotech companies. It signed a contract with a leading Japanese company to develop different peptides using their proprietary technology. In December 2016 Company sold its stake in subsidiary Hikal International B.V. In 2017 it sold the R&D unit in Bangalore. The Company issued Bonus Shares on 26 June 2018 in the ratio of 1:2 i.e. one bonus equity share of Rs. 2/- each fully paid-up for every two existing equity shares of Rs. 2/- each fully paid-up held by the members.In 2023 new product launches in the antidiabetic therapeutic area gained significant traction among global customers. The Company made significant progress on the multi-year Animal Health project with a leading global innovator on developing product portfolio.

Hikal Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

3438

EPS - TTM (₹) [S]

5.82

P/E Ratio (X) [S]

3.00

Face Value (₹) 2
Latest Dividend (%)30.00
Latest Dividend Date 20 Feb 2024
Dividend Yield (%) 0.43
Book Value Share (₹) [S]92.88
P/B Ratio (₹) [S]3.00
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Groww Nifty Total Market Index Fund-Regular (G) 0.01 230 0.01
Groww Nifty Total Market Index Fund-Direct (G) 0.01 230 0.01

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

277.30

283.05

Week Low/High

277.30

288.00

Month Low/High

276.05

308.00

Year Low/High

250.10

329.00

All time Low/High

0.89

742.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-1.76%-1.74%0.820.57%
1 Month-5.94%-6.06%2.932.96%
3 Month-1.92%-1.80%9.2810.22%
6 Month-9.33%-9.60%12.7814.94%
1 Year-7.11%-7.17%24.1328.01%
3 Year74.39%74.44%47.9351.33%

Company Info

Company Information

Non-Exec & Non-Independent Dir : Baba Kalyani

Executive Chairman : Jai Hiremath

Managing Director : Sameer Hiremath

Non-Exec. & Independent Dir. : Kannan Unni

Non-Exec & Non-Independent Dir : Sugandha Hiremath

Non-Exec. & Independent Dir. : Prakash V Mehta

Non-Exec & Non-Independent Dir : Amit B Kalyani

Non-Exec. & Independent Dir. : Ranjit Shahani

Non-Exec. & Independent Dir. : Shivani Bhasin Sachdeva

Company Sec. & Compli. Officer : Rajasekhar Reddy

Independent Director : Shrikrishna K. Adivarekar

Independent Director : Berjis Minoo Desai

Independent Director : V R Kaundinya

Registered Office: 717/718 Maker Chamber V, 7th Floor Nariman Point,Mumbai,Maharashtra-400021 Ph: 91-022-3926 7100/62770477

Email:secretarial@hikal.com/info@hikal.com

URL:http://www.hikal.com